(Q36967864)

17 August 2017

An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors (English)

1 reference

17 August 2017

Tsuyoshi Takahashi

1

1 reference

17 August 2017

Kiyokazu Nakajima

2

1 reference

17 August 2017

Akiko Nishitani

3

1 reference

17 August 2017

Yoshihito Souma

4

1 reference

17 August 2017

Seiichi Hirota

5

1 reference

17 August 2017

Yoshiki Sawa

6

1 reference

17 August 2017

Toshirou Nishida

7

1 reference

17 August 2017

22 October 2007

1 reference

International Journal of Clinical Oncology

17 August 2017

1 reference

17 August 2017

12

1 reference

17 August 2017

5

1 reference

17 August 2017

369-374

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-007-0705-7

17 August 2017

0 references

cites work

Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10147-007-0705-7

Management of gastrointestinal stromal tumors in the imatinib era: selected case studies

21 January 2018

1 reference

12 December 2020

Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

12 December 2020

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Requirement of c-kit for development of intestinal pacemaker system

1 reference

12 December 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

12 December 2020

Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene

1 reference

12 December 2020

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

1 reference

12 December 2020

A study of histopathological assessment criteria for assessing malignancy of gastrointestinal stromal tumor, from a clinical standpoint

1 reference

12 December 2020

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

1 reference

12 December 2020

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy

1 reference

12 December 2020

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate

1 reference

12 December 2020

Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review

1 reference

12 December 2020

Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.

1 reference

12 December 2020

10.1007/S10147-007-0705-7

Identifiers

DOI

1 reference

17 August 2017

1 reference